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Cost-effectiveness of intermittent preventive treatment 
with dihydroartemisinin–piperaquine for malaria during 
pregnancy: an analysis using efficacy results from Uganda 
and Kenya, and pooled data
Silke Fernandes, Vincent Were, Julie Gutman, Grant Dorsey, Abel Kakuru, Meghna Desai, Simon Kariuki, Moses R Kamya, Feiko O ter Kuile, Kara Hanson
Summary
Background Prevention of malaria infection during pregnancy in HIV-negative women currently relies on the use of 
long-lasting insecticidal nets together with intermittent preventive treatment in pregnancy with sulfadoxine–
pyrimethamine (IPTp-SP). Increasing sulfadoxine–pyrimethamine resistance in Africa threatens current prevention 
of malaria during pregnancy. Thus, a replacement for IPTp-SP is urgently needed, especially for locations with high 
sulfadoxine–pyrimethamine resistance. Dihydroartemisinin–piperaquine is a promising candidate. We aimed to 
estimate the cost-effectiveness of intermittent preventive treatment in pregnancy with dihydroartemisinin–
piperaquine (IPTp-DP) versus IPTp-SP to prevent clinical malaria infection (and its sequelae) during pregnancy.
Methods We did a cost-effectiveness analysis using meta-analysis and individual trial results from three clinical trials 
done in Kenya and Uganda. We calculated disability-adjusted life-years (DALYs) arising from stillbirths, neonatal 
death, low birthweight, mild and moderate maternal anaemia, and clinical malaria infection, associated with malaria 
during pregnancy. Cost estimates were obtained from data collected in observational studies, health-facility costings, 
and from international drug procurement databases. The cost-effectiveness analyses were done from a health-care 
provider perspective using a decision tree model with a lifetime horizon. Deterministic and probabilistic sensitivity 
analyses using appropriate parameter ranges and distributions were also done. Results are presented as the 
incremental cost per DALY averted and the likelihood that an intervention is cost-effective for different cost-
effectiveness thresholds.
Findings Compared with three doses of sulfadoxine–pyrimethamine, three doses of dihydroartemisinin–piperaquine, 
delivered to a hypothetical cohort of 1000 pregnant women, averted 892 DALYs (95% credibility interval 274 to 1517) 
at an incremental cost of US$7051 (2653 to 13 038) generating an incremental cost-effectiveness ratio (ICER) of 
$8 (2 to 29) per DALY averted. Compared with monthly doses of sulfadoxine–pyrimethamine, monthly doses of 
dihydroartemisinin–piperaquine averted 534 DALYS (–141 to 1233) at a cost of $13 427 (4994 to 22 895), resulting in 
an ICER of $25 (–151 to 224) per DALY averted. Both results were highly robust to most or all variations in the 
deterministic sensitivity analysis.
Interpretation Our findings suggest that among HIV-negative pregnant women with high uptake of long-lasting 
insecticidal nets, IPTp-DP is cost-effective in areas with high malaria transmission and high sulfadoxine–
pyrimethamine resistance. These data provide a comprehensive overview of the current evidence on the cost-
effectiveness of IPTp-DP. Nevertheless, before a policy change is advocated, we recommend further research into the 
effectiveness and costs of different regimens of IPTp-DP in settings with different underlying sulfadoxine–
pyrimethamine resistance.
Funding Malaria in Pregnancy Consortium, which is funded through a grant from the Bill & Melinda Gates Foundation 
to the Liverpool School of Hygiene and Tropical Medicine.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Malaria infection in pregnancy is associated with 
detrimental outcomes in the mother and the neonate, 
including foetal loss, low birthweight, maternal anaemia, 
and occasionally maternal or neonatal death.1,2 In 2007, an 
estimated 30 million pregnancies occurred in the WHO 
African region in areas where Plasmodium falciparum is 
endemic.3 Without prevention, approximately 45% of 
livebirths in sub-Saharan Africa would be exposed in 
utero to Plasmodium infection, with most infections 
remaining asymptomatic in high transmission settings 
and resulting in adverse outcomes.4 Prevention of malaria 
infection in pregnancy in malaria-endemic settings is 
therefore crucial, and is a public health priority.
To prevent malaria infection, WHO currently 
recommends insecticidal nets combined with monthly 
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intermittent preventive treatment in pregnancy with 
sulfadoxine–pyrimethamine (IPTp-SP) from the second 
trimester onwards in HIV-negative women, or daily co-
trimoxazole prophylaxis in HIV-positive women.5 Despite 
high antenatal care attendance, coverage of IPTp-SP 
remains low in many settings.2,6,7 In addition, growing 
resistance of Plasmodium to sulfadoxine–pyrimethamine 
now threatens the effectiveness of intermittent preventive 
treatment for malaria in parts of sub-Saharan Africa. Thus 
it is crucial to identify an alternative to IPTp-SP.8
Three recent clinical trials, one in western Kenya and 
two in eastern Uganda, found that intermittent preven-
tive treatment in pregnancy with dihydroartemisinin–
piperaquine (IPTp-DP) was effective in reducing clinical 
malaria in pregnancy and its sequelae, and was well 
tolerated when compared with IPTp-SP.9–12 We refer to 
these trials as the Kenya,12 Uganda-I,11 and Uganda-II10 
trials. Two of these trials compared a maximum of 
three or four doses of dihydroartemisinin–piperaquine 
(IPTp-DP3) versus three doses of sulfadoxine–
pyrimethamine (IPTp-SP3). In the Uganda-I trial, the 
researchers included a third group in which women 
received a monthly dose of IPTp-DP (IPTp-DPmonthly).11,12 
The Uganda-II trial compared IPTp-DPmonthly with 
monthly doses of IPTp-SP (IPTp-SPmonthly; appendix p 2).10
We estimated the cost-effectiveness of these inter-
ventions in terms of their impact on preventing clinical 
malaria and its sequelae, summarised as disability-
adjusted life-years (DALYs), in a decision tree model 
using the individual trial results and findings from the 
first two trials pooled by meta-analysis.11,12 Cost-
effectiveness analysis results presented here compare: 
IPTp-DP3 versus IPTp-SP3, using individual trial and 
pooled estimates from the Kenya trial and the Uganda-I 
trial;11,12 IPTp-DPmonthly versus IPTp-DP3 and IPTp-SP3, 
using data from the Uganda-I trial;11 and finally IPTp-
DPmonthly versus IPTp-SPmonthly, using data from the 
Uganda-II trial.10
Methods
Study design and participants
We used outcome data from three clinical trials in Siaya 
County in western Kenya, and Tororo and Busia District 
in eastern Uganda, which enrolled HIV-negative 
Research in context
Evidence before this study
Monthly administration of intermittent preventive treatment in 
pregnancy  with sulfadoxine–pyrimethamine (IPTp-SP) is 
recommended by WHO to prevent malaria in HIV-negative 
women. Growing resistance to sulfadoxine–pyrimethamine 
threatens its effectiveness and alternative treatments are 
urgently needed. We did a literature review on prevention of 
malaria in pregnancy which was published in The Lancet 
Infectious Diseases in 2018. In addition, we searched PubMed on 
Sept 25, 2019, with the keywords “malaria” AND “pregnancy” 
AND “intermittent preventive treatment”, restricted to studies 
from 2017 onwards. Three trials of intermittent preventive 
treatment in pregnancy with dihydroartemisinin–piperaquine 
(IPTp-DP) were done in areas of high resistance to sulfadoxine–
pyrimethamine, one in Kenya and two in Uganda. These trials 
compared IPTp-DP with IPTp-SP using different combinations of 
three doses or monthly administration of either drug 
combination. In all three trials, IPTp-DP was well tolerated, 
effective, and acceptable, suggesting that dihydroartemisinin–
piperaquine is a promising preventive treatment candidate. 
However, to our knowledge, no cost-effectiveness analysis has 
been done to date. 
Added value of this study
We estimated the cost-effectiveness of IPTp-DP regimens, 
using three different comparisons, in terms of prevention of 
clinical malaria and its sequelae from the health-care provider 
perspective using both individual trial results and, where 
possible, results pooled by meta-analysis. The cost-
effectiveness comparing three doses of dihydroartemisinin–
piperaquine with three doses of sulfadoxine–pyrimethamine 
using pooled data resulted in a highly cost-effective 
incremental cost-effectiveness ratio (ICER) of US$8 per 
disability-adjusted life year (DALY) averted. Similarly, 
the comparison of monthly doses of dihydroartemisinin–
piperaquine (IPTp-DPmonthly) versus monthly doses of 
sulfadoxine–pyrimethamine (IPTp-SPmonthly), using data from the 
second Uganda trial, produced a highly cost-effective ICER of 
$25 per DALY averted. However, IPTp-DPmonthly was less effective 
and more costly than IPTp-DP3 and IPTp-SP3, driven by a 
small, non-significant increase in neonatal deaths in the 
IPTp-DPmonthly group of the first Uganda trial; a study with a 
small sample size of only 100 women per group. To address 
this, sensitivity scenarios modelling neonatal death were 
explored, generating highly cost-effective ICERs for 
IPTp-DPmonthly versus IPTp-DP3 and IPTp-SP3 ranging from $34 
to $100 per DALY averted. For all three cost-effectiveness 
analyses, the likelihood of IPTp-DP being cost-effective, 
calculated using probabilistic sensitivity analysis, was high with 
respect to country-level cost-effectiveness thresholds for the 
base case scenario and in the latter analysis for the scenario in 
which neonatal death was modelled. 
Implications of all the available evidence
Our results indicate that both IPTp-DP regimens are likely to be 
highly cost-effective at preventing malaria during pregnancy in 
settings of similar endemicity and sulfadoxine–pyrimethamine 
resistance. These results support earlier findings on the efficacy, 
safety, and acceptability of dihydroartemisinin–piperaquine, 
showing IPTp-DP could be a viable alternative strategy to 
prevent malaria during pregnancy in HIV-negative women. 
See Online for appendix
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pregnant women of all gravidities who had a high uptake 
of long-lasting insecticidal nets.10–12 To our knowledge, 
there are no other similar trials published. Although 
located in two different countries, the three trial sites are 
only a maximum of 110 km apart. The sites share a high 
intensity of malaria transmission and the effectiveness 
of IPTp-SP is compromised by widespread parasite 
resistance to sulfadoxine–pyrimethamine as a result of 
single-nucleotide polymorphisms in the P falciparum 
dihydrofolate reductase (dhfr) and dihydropteroate 
synthetase (dhps) genes. The prevalence of sulfadoxine–
pyrimethamine quintuple-mutant parasites (a biomarker 
of resistance to sulfadoxine–pyrimethamine) is high, but 
the prevalence of the sextuple mutant is less than 6%.13 
The Kenya trial randomly assigned 1031 women to 
receive either IPTp-SP3 (n=515) or IPTp-DP3 (n=516).12 
A third group were assigned to receive intermittent 
screening followed by treatment with dihydroartemisinin–
piperaquine, which was found to be unsuitable to replace 
IPTp-SP because of a lack of clinical efficacy, and this 
group was excluded from this cost-effectiveness analysis. 
The Uganda-I trial in Tororo, Uganda, randomly assigned 
300 women to one of three groups, IPTp-SP3 (n=106), 
IPTp-DP3 (n=94), or IPTp-DPmonthly (n=100).11 The 
Uganda-II trial, in Busia District, Uganda, randomly 
assigned 782 women to either IPTp-DPmonthly (n=391) or 
IPTp-SPmonthly (n=391).10
Baseline characteristics were generally similar between 
the trials. In the Kenya trial, the gestational age of women 
at enrolment was 16–32 weeks (mean 22·8–23·0 weeks 
depending on group),12 while in the Uganda trials it was 
12–20 weeks (mean 15·2–15·5 weeks in the Uganda-I 
trial11 and 15·0–15·4 weeks in the Uganda-II trial10). 
Women in the Uganda-I trial were on average younger 
than in the other two trials (mean 22·2 years vs 23·4 years 
in the Kenya trial and 23·0 years in the Uganda-II trial). 
Women in the Kenya trial received on average 2·7 doses 
of treatment in both groups; women in the Uganda-I trial 
received 2·8 (IPTp-SP3), 2·9 (IPTp-DP3), and 5·9 doses 
(IPTp-DPmonthly); and women in the Uganda-II trial 
received 6·0 doses in both groups. The mean haemo-
globin at baseline was lower in women in the Kenya trial 
compared with women in the Uganda trials (105 g/L in 
the Kenya trial vs 119 g/L in the Uganda-I trial and 115 g/L 
in the Uganda-II trial). Details of the study sites, 
trial design, participant characteristics, key outcomes, 
and sample size calculations have been previously 
published,10–12 and an overview is provided in the appendix 
(pp 3–4).
Effects
Model outcomes were selected on the basis of clinical and 
economic relevance and availability of disability weights 
to calculate DALYs. Both child and maternal outcomes 
were included, namely neonatal death, stillbirth, low 
birthweight (<2·5 kg), maternal anaemia (haemoglobin 
<110 g/L for Kenya and Uganda-I and <100 g/L for 
Uganda-II), and clinical malaria. Separate decision tree 
models were developed for all child outcomes (neonatal 
death, stillbirth, and low birth weight), maternal anaemia, 
and clinical malaria (appendix pp 5–8), because disability 
weights for concurrent events (ie, maternal anaemia and 
clinical malaria) are unknown. In the decision tree for 
child outcomes, neonatal death branches off before low 
birthweight, as birthweight was not recorded for all babies 
and priority was given to the most severe outcome. 
Prevalence and incidence data in the model incorporated 
the individual trial results. Pooled effect estimates 
combining the effect of IPTp-DP3 versus IPTp-SP3 from 
the Kenya and Uganda-I trials were obtained using fixed-
effects meta-analyses. DALYs were calculated by adding 
up the DALYs from all outcomes included in the model. 
Other serious adverse events and tolerance measures 
documented in the trial were excluded from the model 
(for both effect and cost), as no study drug-related 
difference in their incidence was recorded.
All three trials concluded that IPTp-DP was efficacious; 
however, the main outcomes driving their conclusions 
differed among the trials. Both the Kenya trial and the 
Uganda-II trial found a lower number of stillbirths and 
neonatal deaths in the IPTp-DP group, and the Uganda-I 
trial identified no difference in stillbirths, but a small, 
non-significant increase in neonatal deaths, probably 
occurring by chance because of the small sample size 
of the trial. The number of low birthweight babies in 
the IPTp-DP group increased in the Kenya trial, but was 
lower in both of the Uganda trials. Only the Uganda-II 
trial found a decrease in maternal anaemia in the 
IPTp-DP group, and in the other trials the level of anaemia 
was relatively similar between IPTp-SP and ITPp-DP 
groups. Finally, in all three trials, episodes of clinical 
malaria were substantially lower in all IPTp-DP groups.
Costs
We adopted a health-care provider perspective to estimate 
the incremental fixed and variable costs of delivering 
the interventions and their cost savings. The costs of 
nurses’ time, drugs, and of treating consequential health 
outcomes of malaria infection in pregnancy, comprising 
maternal anaemia, maternal clinical malaria, and post-
delivery hospitalisation costs for low birthweight, were 
included. Health-care provider costs of a neonatal death 
or stillbirth (such as mortuary costs) were not collected 
because we did not anticipate these outcomes would 
drive the trials results, and hence these costs are excluded 
from the cost estimation. Cost data were collected by 
doing an observational study of trial participants in 
Kenya to measure the average admini stration time for 
intermittent preventive treat ment (n=44) which was 
multiplied by the mean cost of nurses’ time to estimate 
the total cost of nurses’ time per administration; health-
care facility costings (n=4) to estimate the costs of malaria 
infection during pregnancy and its sequelae; and an 
analysis of international drug procurement databases to 
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calculate the drug prices per administration.14 The cost of 
nurses’ time was estimated by averaging salaries and 
benefits provided to nurses obtained from Ministries of 
Health in Kenya and Uganda for 2018. For all costs, 
economic costs were calculated and valued in constant 
2018 US$ using the local consumer price index and 
average 2018 exchange rates.15,16 No health-care facility 
costing was done in Uganda. Therefore, the costs of 
malaria infection during pregnancy (and its conse-
quences) from Kenya were used for Uganda, adjusting 
costs by the ratio of average nurse salaries in the two 
countries, which was 0·30 (ie, nurses’ salaries in Uganda 
are 30% of those in Kenya). Ex-factory drug prices 
from procurement databases were adjusted for insurance 
and freight (10%), in-country transport (10%), and 
wastage (5%). Assumptions used in calculating costs 
of maternal anaemia and malaria infection during 
pregnancy are published elsewhere.14
All cost and observational data collection was approved 
by the ethics committees of the London School of 
Hygiene & Tropical Medicine, US Centers for Disease 
Control and Prevention, and the Kenya Medical Research 
Institute. Verbal consent was obtained from each 
participant being observed.
Statistical analysis
Outcome data for IPTp-SP3 and IPTp-DP3 from the 
Uganda-I and Kenya trials were pooled using both fixed-
effects and random-effects meta-analysis models, with 
the effect of the random-effects model explored in the 
sensitivity analysis. Because we followed the structure of 
the decision trees, the results are slightly different from 
Base case Distribution Source
Health-care worker time costs
Time nurses take to provide one dose of preventive treatment in Kenya, s 
(95% CI) 
377·16 (254·28–500·04) Gamma Observational study of trial participants, Kenya (n=44)
Mean number of doses per woman in the IPTp-SP3 group (Kenya) 2·74 Point estimate Desai et al (2015)12
Mean number of doses per woman in the IPTp-DP3 group (Kenya) 2·71 Point estimate Desai et al (2015)12
Mean number of doses per woman in the IPTp-SP3 group (Uganda-I) 2·82 Point estimate Kakuru et al (2016)11
Mean number of doses per woman in the IPTp-DP3 group (Uganda-I) 2·85 Point estimate Kakuru et al (2016)11
Mean number of doses per woman in the IPTp-DPmonthly group (Uganda-I) 5·94 Point estimate Kakuru et al (2016)11
Mean number of doses per woman in the IPTp-SPmonthly group (Uganda-II) 6·00 Point estimate Kajubi et al (2019)10
Mean number of doses per woman in the IPTp-DPmonthly group (Uganda-II) 6·00 Point estimate Kajubi et al (2019)10
Nurses’ monthly cost of labour in Kenya, US$ (range) 1037·86 (1002·84–1072·88) Gamma Ministry of Health, Kenya (2018)
Nurses’ monthly cost of labour in Uganda, $ (range) 306·30 (219·71–392·89) Gamma Ministry of Health, Uganda (2018)
Drug costs
International sulfadoxine–pyrimethamine price per tablet, $ (95% CI) 0·07 (0·05–0·08) Gamma International drug price list (2015) adjusted for inflation and 
Global Fund procurement database (2018)23,24
International dihydroartemisinin–piperaquine price per tablet, $ (95% CI) 0·25 (0·22–0·29) Gamma International drug price list (2015) adjusted for inflation and 
Global Fund procurement database (2018)23,24
Mean number of tablets per dose of sulfadoxine–pyrimethamine 3·00 Point estimate Desai et al (2015); Kakuru et al (2016); and Kajubi et al (2019)10–12
Mean number of tablets per dose of dihydroartemisinin–piperaquine 9·00 Point estimate Desai et al (2015); Kakuru et al (2016); and Kajubi et al (2019)10–12
Costs from adverse health outcomes
Cost per inpatient day excluding medical supplies, US$ 2013 (to be adjusted 
for inflation; SD=35·88; Kenya; 95% CI)
37·12 (α=1·07, β=34·68; 
1·10–131·20)
Gamma Health-care facility costing, Kenya (n=4)
Cost per outpatient visit excluding medical supplies, US$ 2013 (to be adjusted 
for inflation; SD=1·28; Kenya; 95% CI)
3·73 (α=33·97, β=0·11; 
2·60–5·10)
Gamma Health-care facility costing, Kenya (n=4)
Adjustment factor for costs of inpatient and outpatient costs for Uganda 0·30 Point estimate Ratio of Ministry of Health nurses’ salaries, Uganda and Kenya
Incremental time in hospital for low birthweight vs normal birthweight in 
Kenya, days (95% CI; p value)
2·38 (1·76–3·00; 
p<0·0001)
Gamma Kenya trial post-partum health utilisation form (low 
birthweight n=48, normal birthweight n=982)
Parameters and assumptions to calculate cost per moderate anaemia and malaria in pregnancy episode
Short-term cost per low birthweight baby (Kenya), $ (95% CI) 121·86 (3·54–437·74) NA Probabilistic sensitivity analysis
Short-term cost per low birthweight baby (Uganda), $ (95% CI) 35·97 (1·04–129·19) NA Probabilistic sensitivity analysis
Short-term cost per low birthweight baby (meta-analysis), $ (95% CI) 78·91 (2·29–283·46) NA Probabilistic sensitivity analysis
Cost per moderate anaemia episode (Kenya), $ (95% CI) 10·01 (4·21–25·49) NA Probabilistic sensitivity analysis
Cost per moderate anaemia episode (Uganda), $ (95% CI) 4·78 (2·41–9·75) NA Probabilistic sensitivity analysis
Cost per moderate anaemia episode (meta-analysis), $ (95% CI) 7·39 (3·34–17·73) NA Probabilistic sensitivity analysis
Cost per malaria in pregnancy episode (Kenya), $ (95% CI) 12·40 (3·51–36·11) NA Probabilistic sensitivity analysis
Cost per malaria in pregnancy episode (Uganda), $ (95% CI) 5·49 (2·01–13·06) NA Probabilistic sensitivity analysis
Cost per malaria in pregnancy episode (meta-analysis), $ (95% CI) 8·95 (2·79–24·59) NA Probabilistic sensitivity analysis
(Table 1 continues on next page)
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the results reported by Desai and colleagues8 in a review 
and meta-analysis. The cost-effectiveness of IPTp-DP3 
versus IPTp-SP3 (pooled estimate); IPTp-DPmonthly versus 
IPTp-DP3 and IPTp-SP3 (Uganda-I); and IPTp-DPmonthly 
versus IPTp-SPmonthly (Uganda-II), was analysed based 
on the decision trees from the health-care provider 
perspective using a lifetime horizon to reflect the lifelong 
mortality and morbidity effects of the adverse health 
outcomes of malaria infection during pregnancy. DALYs 
were calculated and then summed for all child and 
maternal outcomes using disability weights from Global 
Burden of Disease studies,17–19 case fatality rates from 
secondary literature (except for low birthweight, which is 
captured in the mortality estimates of the trials),20,21 and 
local life expectancies, with no age weighting, and a 
discount rate of 3%.22
The results were expressed as an incremental cost-
effectiveness ratio (ICER) for a hypothetical cohort of 
1000 pregnant women, calculated by dividing the 
incremental costs of the intervention by the DALYs 
averted—ie,
The robustness of our results was tested using 
deterministic and probabilistic sensitivity analysis. The 
probabilistic sensitivity analysis included 10 000 iterations, 
producing a point estimate for each iteration (a simulation 
point), which was plotted in the cost-effectiveness plane. 
Subsequently, using all 10 000 iterations, the mean, 
median, and credibility intervals (CrIs; a 95% CI based on 
percentiles) of the differences in costs, effects, and ICER 
were calculated. Appropriate distributions were assigned 
to each parameter following cost-effectiveness guidelines 
(tables 1, 2).22 For zero events (neonatal death in IPTp-SP3 
group and clinical malaria in the IPTp-DPmonthly group in 
the Uganda-I trial), a transformation of 0 plus 0·1 was 
used in the probabilistic sensitivity analysis to be 
able to model uncertainty of these parameters using 
distributions. The probabilistic sensitivity analysis results 
were compared with multiple country-specific cost-
effectiveness thresholds and, for each threshold, the 
likelihood of being cost-effective was calculated. The 
cost-effectiveness thresholds were calculated by using 
estimates of country-level thresholds by Woods and 
colleagues27 and Ochalek and colleagues,28 adjusted for 
inflation. These thresholds ranged from $79·8 to $1273·1 
for Kenya and from $30·6 to $793·0 for Uganda. Cost-
effectiveness thresholds should be used as a guide for 
interpreting the results, rather than as an actual cutoff 
for cost-effectiveness. The Uganda-I trial was relatively 
small compared to the other trials (300 participants vs 
1031 participants in the Kenya trial and 782 participants in 
Base case Distribution Source
(Continued from previous page)
DALY calculations
Discount rate (range) 0·03 (0·00–0·05) Point estimate  Assumption 
Mean age, years (95% CI; Kenya) 23·40 (22·89–23·91) Normal Desai et al (2015)12
Mean age, years (95% CI; Uganda-I) 22·20 (21·33–23·07) Normal Kakuru et al (2016)11
Mean age, years (95% CI; Uganda-II) 23·00 (22·40–23·60) Normal Kajubi et al (2019)10
Life expectancy for women aged 20–24 years, years (Kenya, 2016) 53·30 Point estimate Global health observatory data repository, WHO25
Life expectancy at birth, years (Kenya, 2016) 66·65 Point estimate Global health observatory data repository, WHO25
Life expectancy for women aged 20–24 years, years (Uganda, 2016) 49·90 Point estimate Global health observatory data repository, WHO25
Life expectancy at birth, years (Uganda, 2016) 62·50 Point estimate Global health observatory data repository, WHO25
Length of disability: malaria during pregnancy, days (range) 3·5 (2·0–6·0) Gamma Assumption
Length of disability: malaria related anemia, days (range) 21·0 (14·0–42·0) Gamma Price et al (2001)26
Length of disability: low birthweight Lifelong NA Global health observatory data repository, WHO25
Disability weight of severe infectious disease; acute episode (95% CI) 0·21 (0·14–0·30) Log normal GBD 2010 disability weights17*
Disability weight of mild maternal anaemia (95% CI) 0·004 (0·001–0·008) Log normal GBD 2015 disability weights19
Disability weight of moderate maternal anaemia (95% CI) 0·05 (0·03–0·08) Log normal GBD 2015 disability weights19
Disability weight of low birthweight 0·11 (0·07–0·14) Log normal GBD 2004 update, plus or minus 30%18
Case fatality rate from malaria during pregnancy, %† 0·33 (0·26–0·45) Beta Sicuri et al (2010)21
Case fatality rate from moderate or severe anaemia in pregnancy, %† 1·00 (0·80–1·20) Beta Brabin el al (2001), plus or minus 20%20
Case fatality rate from mild anaemia in pregnancy, % 0·00 Point estimate Assumption
Mild anaemia was haemoglobin between 90 and <110 g/L, moderate anaemia was haemoglobin <90 g/L. Low birthweight was <2·5 kg. DALY=disability-adjusted life-year. IPTp-SP3=intermittent preventive 
treatment in pregnancy with three doses of sulfadoxine–pyrimethamine. IPTp-DP3=intermittent preventive treatment in pregnancy with three doses of dihydroartemisinin–piperaquine. IPTp-DPmonthly=intermittent 
preventive treatment in pregnancy with monthly doses of dihydroartemisinin–piperaquine. IPTp-SPmonthly=intermittent preventive treatment in pregnancy with monthly doses of sulfadoxine–pyrimethamine. 
α=shape parameter. β=rate parameter of the distribution. NA=not applicable. GBD=Global Burden of Disease study. *GBD 2015 estimates for malaria were not used, but we used GBD 2012 estimate for severe 
episode of infectious disease. †Distribution fitted by method of moments.
Table 1: Cost and DALY input parameters
ICER=
(DALYIPTp-SP3–DALYIPTp-DP3)
(CostsIPTp-DP3–CostsIPTp-SP3)
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the Uganda-II trial). The Uganda-I trial reported one 
stillbirth in each group, and zero neonatal deaths 
in 98 participants in the IPTp-SP3 group, two (2%) in 
88 participants in the IPTp-DP3 group, and three (3%) 
in 97 participants in the IPTp-DPmonthly group. All five 
neonatal deaths in the Uganda-I trial occurred in the first 
3 days of life and the causes of death were prematurity 
related complications. These differences in number of 
neonatal deaths were not significant; however, when these 
numbers are extrapolated to a hypothetical cohort of 
1000 women in our models, the IPTp-DPmonthly group can 
never be more cost-effective than the other treatment 
regimens, because of the higher number of neonatal 
deaths in this group. The numbers of stillbirths and 
neonatal deaths in the three groups in the Uganda-I trial 
are very small; therefore the differences among the groups 
cannot be estimated precisely and might have occurred by 
chance (table 2). Therefore, although we used the trial 
results in the base case analysis, we also modelled 
mortality in the deterministic sensitivity analysis for 
the cost-effectiveness analysis of IPTp-DPmonthly versus 
IPTp-DP3 and IPTp-SP3.
Analysis of the observations of nurses’ time to 
administer the intervention and the meta-analysis of 
outcomes was done using STATA version 15, and the 
international procurement data analysis, health-care 
facility costing studies, and the cost-effectiveness 
modelling were done in Microsoft Excel (using Visual 
Basic for Applications for the probabilistic sensitivity 
analysis). Our analytical and reporting methodology was 
guided by the Gates Reference Case.22
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. SF and KH had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Kenya Uganda-I Uganda-II Meta-analysis Distribution
Child outcomes
Stillbirths
IPTp-SP3 group (α/β) 35·32 (16/437) 10·10 (1/98) NA 30·80 (17/535) Beta
IPTp-DP3 group (α/β) 8·85 (4/448) 11·24 (1/88) NA 9·24 (5/536) Beta
IPTp-SPmonthly group (α/β) NA NA 14·97 (5/329) NA Beta
IPTp-DPmonthly group (α/β) NA 10·20 (1/97) 5·90 (2/337) NA Beta
Neonatal deaths
IPTp-SP3 group (α/β) 27·46 (12/425) 0 (0/98)* NA 22·43 (12/523) Beta
IPTp-DP3 group (α/β) 8·93 (4/444) 22·73 (2/86) NA 11·19 (6/530) Beta
IPTp-SPmonthly group (α/β) NA NA 18·24 (6/323) NA Beta
IPTp-DPmonthly group (α/β) NA 30·93 (3/94) 11·87 (4/333) NA Beta
Low birthweight
IPTp-SP3 group (α/β) 32·18 (13/391) 132·65 (13/85) NA 51·79 (26/476) Beta
IPTp-DP3 group (α/β) 53·14 (22/392) 127·91 (11/75) NA 66·00 (33/467) Beta
IPTp-SPmonthly group (α/β) NA NA 89·78 (29/294) NA Beta
IPTp-DPmonthly group (α/β) NA 74·47 (7/87) 72·07 (24/309) NA Beta
Maternal outcomes
Mild anaemia (Hb between 90 and <110 g/L) or moderate anaemia (Hb <90 g/L)
IPTp-SP3 group, mild/moderate (α1/α2/β)† 469·33/82·67 (176/31/168) 336·74/81·63 (33/8/57) NA 441·86/82·45 (209/39/225) Dirichlet
IPTp-DP3 group, mild/moderate (α1/α2/β)† 502·70/56·76 (186/21/163) 311·11/11·11 (28/1/61) NA 465·22/47·83 (214/22/224) Dirichlet
IPTp-SPmonthly group, mild/moderate (α1/α2/β)† NA NA 196·55 (171/699)‡ NA Beta
IPTp-DPmonthly group, mild/moderate (α1/α2/β)† NA 282·83/50·51 (28/5/66) 98·45 (89/815)‡ NA Dirichlet or beta
Clinical malaria
IPTp-SP3 group (α1/α2/α3/β)§ 123·46 (52/4/0/430) 386·79 (23/9/0/74) NA 170·61 (75/13/0/504) Dirichlet
IPTp-DP3 group (α1/α2/α3/β)§ 26·80 (8/1/1/475) 127·66 (10/1/0/83) NA 43·17 (18/2/1/558) Dirichlet
IPTp-SPmonthly group (α1/α2/α3/β)§ NA NA 221·90 (75/263)¶ NA Beta
IPTp-DPmonthly group (α1/α2/α3/β)§ NA 0 (0/0/0/99) 8·60 (3/346)¶ NA Dirichlet or beta
Data are shown as events per 1000 women following the decision tree, as well as α (events) and β (no events). Low birthweight was <2·5 kg. IPTp-SP3=intermittent preventive treatment in pregnancy with 
three doses of sulfadoxine–pyrimethamine. NA=not applicable. IPTp-DP3=intermittent preventive treatment in pregnancy with three doses of dihydroartemisinin–piperaquine. IPTp-SPmonthly=intermittent 
preventive treatment in pregnancy with monthly doses of sulfadoxine–pyrimethamine. IPTp-DPmonthly=intermittent preventive treatment in pregnancy with monthly doses of dihydroartemisinin–piperaquine. 
Hb=haemoglobin. *Transformation for probabilistic sensitivity analysis: αt=α + 0·1, βt=β – 0·1. †α1=mild anaemia events; α2=moderate anaemia events; β=no events. ‡Only α2=moderate anaemia and β=no events 
are given for Uganda-II. §α1=one episode of clinical malaria; α2=two episodes of clinical malaria; α3=three episodes of clinical malaria; β=no events. ¶Only α=episodes of malaria and β=no events are given for 
Uganda-II.
Table 2: Measures of effect
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Results
The meta-analysis results are shown in the appendix 
(pp 9–12). Maternal malaria and moderate anaemia 
outcomes were better with IPTp-DP3 than with IPTp-
SP3, but there was no difference in mild anaemia.  For 
the child health outcomes, stillbirth and neonatal death 
were better with IPTp-DP3, but low birthweight was 
marginally better in the IPTp-SP3 group. Here we report 
deterministic results, followed by the CrIs from the 
probabilistic sensitivity analysis.
The incremental effectiveness per 1000 pregnant 
women of IPTp-DP3 versus IPTp-SP3 was 892 DALYs 
averted (95% CrI 274 to 1517; table 3). The incremental 
effectiveness of IPTp-DPmonthly compared with IPTp-DP3 
was –44 DALYS averted (–1575 to 1472) and compared 
with IPTp-SP3 was –646 DALYs averted (–1976 to 528). 
The negative DALYs can be attributed to a small, non-
significant increase in child mortality outcomes in both 
IPTp-DP groups in the Uganda-I trial, which was a 
small trial (n=300) with insufficient statistical power to 
detect a difference in mortality outcomes. Finally, the 
incremental effectiveness of IPTp-DPmonthly compared 
with IPTp-SPmonthly was 534 DALYs averted (–141 to 1233). 
The health outcomes contributing most to a positive 
Kenya 
(IPTp-DP3 vs 
IPTp-SP3)
Uganda-I 
(IPTp-DP3 vs 
IPTp-SP3)
Uganda-I 
(IPTp-DPmonthly vs 
IPTp-SP3)
Uganda-I 
(IPTp-DPmonthly vs 
IPTp-DP3)
Uganda-II 
(IPTp-DPmonthly vs 
IPTp-SPmonthly)
Meta-analysis 
(IPTp-DP3 vs 
IPTp-SP3)
Costs
Incremental costs per 1000 women including 
costs from consequences, US$ 2018
8201 
(8230 
[3176 to 16 688])
5467 
(5403 
[–1918 to 11 623])
12 406 
(12 391 
[508 to 22 789])
6939 
(6988 
[–1934 to 12 989])
13 427 
(13 310 
[4994 to 22 895])
7051 
(7080 
[2653 to 13 038])
Outcomes averted
Low birthweight cases averted per 1000 women –22 
(–22 [–50 to 4])
8 
(8 [–89 to 100])
60 
(60 [–22 to 144])
52 
(52 [–30 to 140])
18 
(18 [–24 to 60])
–16 
(–16 [–44 to 13])
Stillbirth cases averted per 1000 women 26 
(26 [8 to 47])
–1 
(–1 [–33 to 31])
0 
(0 [–30 to 31])
1 
(1 [–30 to 33])
9 
(9 [–5 to 25])
22 
(22 [6 to 39])
Neonatal death averted per 1000 women 18 
(18 [2 to 36])
–22 
(–21 [–62 to –1])
–31 
(–29 [–71 to –5])
–8 
(–8 [–56 to 39])
6 
(6 [–12 to 26])
11 
(11 [–4 to 26])
Mild anaemia cases averted per 1000 women –33 
(–34 [–105 to 39])
26 
(26 [–104 to 157])
54 
(55 [–73 to 182])
28 
(28 [–101 to 160])
N/A –23 
(–24 [–89 to 41])
Moderate anaemia cases averted per 1000 women 26 
(26 [–10 to 63])
71 
(71 [19 to 137])
31 
(31 [–37 to 103])
–39 
(–39 [–92 to 5])
98 
(98 [64 to 130])
35 
(35 [3 to 66])
Clinical malaria cases averted per 1000 women 97 
(97 [64 to 130])
259 
(259 [145 to 373])
386 
(386 [296 to 481])
127 
(127 [69 to 201])
213 
(213 [169 to 259])
127 
(128 [93 to 162])
DALYs averted
Total DALYs averted per 1000 women 1220 
(1183 [498 to 1926])
–602 
(–557 [–1913 to 553])
–646 
(–602 [–1976 to 528])
–44 
(–44 [–1575 to 1472])
534 
(522 [–141 to 1233])
892 
(873 [274 to 1517])
ICER
Total cost per DALY averted including costs from 
consequences, US$ 2018
7 
(7 [2 to 22])
–9 
(–10 [–110 to 93])
–19 
(–21 [–219 to 192])
–158 
(–159 [–146 to 166])*
25 
(26 [–151 to 224])
8 
(8 [2 to 29])
Likelihood of being cost-effective (shown as percentage of 10 000 simulations that were cost-effective)
Simulations cost-effective at CET1† 
(Kenya $79·8, Uganda $30·6), %
99·88% 10·15% 4·82% 35·17% 58·75% 99·43%/97·64%§
Simulations cost-effective at CET2† 
(Kenya $676·5, Uganda $411·8), %
99·96% 15·17% 13·39% 46·36% 92·66% 99·74%/99·73%§
Simulations cost-effective at CET3† 
(Kenya $1273·1, Uganda $793·0), %
99·96% 15·45% 13·88% 46·86% 93·24% 99·74%/99·74%§
Simulations cost-effective at CET4‡ 
(Kenya $520·2, Uganda $124·0), %
99·96% 13·87% 10·97% 44·19% 89·20% 99·73%/99·51%§
Simulations cost-effective at CET5‡ 
(Kenya $685·5, Uganda $163·2), %
99·96% 14·24% 11·66% 44·92% 90·34% 99·74%/99·64%§
Results are presented as base case result (mean probabilistic sensitivity analysis result [95% credibility estimates]), unless otherwise stated. All numbers, with the exception of percentages, are presented without 
decimals to ease interpretation of the results. The base case result represents the results of the deterministic base case analysis, where for each parameter the best estimate was used. The numbers in parentheses 
stem from the probabilistic sensitivity analysis, which was done using 10 000 simulations. DALYs and ICERs were estimated including clinical malaria, anaemia, stillbirth, low birthweight, and neonatal death. 
Mild anaemia was haemoglobin between 90 and <110 g/L, moderate anaemia was haemoglobin <90 g/L. Low birthweight was <2·5 kg. A negative effect size number (negative difference in number of events of 
a certain outcome or DALYs averted) indicates the intervention led to more events or DALYs—ie, the intervention was less effective than the comparison regimen for that particular outcome, leading to a negative 
incremental cost-effectiveness ratio. IPTp-DP3=intermittent preventive treatment in pregnancy with three doses of dihydroartemisinin–piperaquine. IPTp-SP3=intermittent preventive treatment in pregnancy 
with three doses of sulfadoxine–pyrimethamine. IPTp-DPmonthly=intermittent preventive treatment in pregnancy with monthly doses of dihydroartemisinin–piperaquine. IPTp-SPmonthly=intermittent preventive 
treatment in pregnancy with monthly doses of sulfadoxine–pyrimethamine. N/A=not available. DALY=disability-adjusted life-year. ICER=Incremental cost-effectiveness ratio. CET=cost-effectiveness threshold. 
*The median value for the ICER was –2·93, which is included in the credibility interval.†Country-level CETs from Woods et al (2016).27 ‡Country-level CETs from Ochalek et al (2018).28 §CET Kenya/CET Uganda.
Table 3: Cost, outcome, and cost-effectiveness results
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difference in DALYs averted differed among the three 
trials. Stillbirth and neonatal death were the main 
drivers for DALYs averted with IPTp-DP3 versus IPTp-
SP3 (pooled data) and for IPTp-DPmonthly versus IPTp-
SPmonthly (Uganda-II), while low birthweight was most 
relevant for the Uganda-I trial, comparing IPTp-DPmonthly 
with IPTp-DP3 or IPTp-SP3.
The incremental cost per 1000 pregnant women of 
IPTp-DP3 compared with IPTp-SP3 was $7051 (95% CrI 
2653 to 13 038). The incremental cost of IPTp-DPmonthly 
compared with IPTp-DP3 was $6939 (–1934 to 12 989) 
and compared with IPTp-SP3 was $12 406 (508 to 22 789). 
Finally, the incremental cost of IPTp-DPmonthly compared 
with IPTp-SPmonthly was $13 427 (4994 to 22 895).
The ICER of IPTp-DP3 compared with IPTp-SP3 was 
$8 (95% CrI 2 to 29) per DALY averted. IPTp-DPmonthly was 
both more costly and less effective than IPTp-DP3 
and IPTp-SP3 if all outcomes are included. The ICER 
of IPTp-DPmonthly compared with IPTp-SPmonthly was $25 
(–151 to 224) per DALY averted.
Using 10 000 simulations for the probabilistic 
sensitivity analysis, the simulation points were plotted 
on the cost-effectiveness planes and the likelihood of a 
scenario being cost-effective was calculated for each 
cost-effectiveness threshold. Comparing IPTp-DP3 with 
IPTp-SP3, the percentage of simulations indicating a 
cost-effective result was more than 97·6% for all cost-
effectiveness thresholds. In contrast, only 35·2–46·9% 
of simulations comparing IPTp-DPmonthly with IPTp-DP3 
and 4·8–13·9% of simulations comparing IPTp-DPmonthly 
with IPTp-SP3 were judged cost-effective against the 
cost-effectiveness thresholds. For the five cost-
effectiveness thresholds considered, 58·8–93·2% of 
simulations comparing IPTp-DPmonthly with IPTp-SPmonthly 
were found to be cost-effective (figure 1, table 3, appendix 
pp 13–17).
In the deterministic sensitivity analysis, for IPTp-DP3 
versus IPTp-SP3 (pooled data, base case ICER $8 per DALY 
averted) all but three variations produced ICERs that 
remained cost-effective relative at all cost-effectiveness 
thresholds (figure 2). Our base case analysis only included 
the short-term costs of low birthweight; therefore, we 
modelled the effect of including an arbitrary cost of low 
birthweight on the ICER in the pooled analysis. Using an 
incremental discounted lifetime cost per low birthweight 
baby of $1000 changed the ICER of IPTp-DP3 compared 
with IPTp-SP3 to $24 per DALY averted and a cost of $5000 
changed the ICER to $94 per DALY averted; IPTp-DP3 
remained cost-effective relative to all cost-effectiveness 
thresholds when using a cost of $1000 per low birthweight 
baby, and relative to all but the lowest cost-effectiveness 
threshold from each country when using a cost of $5000. 
Omitting stillbirth and neonatal death from the outcome 
measurement and then modelling neonatal death from 
low birthweight (with a case fatality rate of 6·93%)29 
resulted in IPTp-DP3 being less effective and more costly 
than IPTp-SP3. Conversely, when comparing IPTp-DPmonthly 
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Figure 1: Cost-effectiveness planes for IPTp-DP3 versus IPTp-SP3 and IPTp-DPmonthly versus IPTp-SPmonthly
Cost-effectiveness planes in a hypothetical cohort of 1000 pregnant women for IPTp-DP3 versus IPTp-SP3, using 
meta-analysis pooled data (A), and IPTp-DPmonthly versus IPTp-SPmonthly, using data from the Uganda-II trial (B). 
Further cost-effectiveness planes comparing IPTp-DP3 with IPTp-SP3, IPTp-DPmonthly with IPTp-DP3, IPTp-DPmonthly 
with IPTp-SP3 (Uganda-I), and IPTp-DP3 with IPTp-SP3 (Kenya) are given in the appendix (pp 13–17). The 
cost-effectiveness planes display the results of the probabilistic sensitivity analysis using 10 000 simulations. Each 
data point represents one simulation, where the value for each parameter is sampled from a distribution. The CETs 
were estimated using country-specific CETs published by Woods et al (2016)27 and Ochalek et al (2018),28 adjusted 
for inflation. IPTp-DP3=intermittent preventive treatment in pregnancy with three doses of dihydroartemisinin–
piperaquine. IPTp-SP3=intermittent preventive treatment in pregnancy with three doses of sulfadoxine–
pyrimethamine. IPTp-DPmonthly=intermittent preventive treatment in pregnancy with monthly doses of 
dihydroartemisinin–piperaquine. IPTp-SPmonthly=intermittent preventive treatment in pregnancy with monthly 
doses of sulfadoxine–pyrimethamine. CET=cost-effectiveness threshold. DALY=disability-adjusted life-year.
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with IPTp-DP3 (appendix p 18), for which the base case 
found IPTp-DPmonthly to be less effective and more costly 
than IPTp-DP3 (ICER –$158 per DALY averted), the 
sensitivity analysis scenario produced an ICER of $26 per 
DALY averted, when investigating the same changes. 
Thus, halving the risk of neonatal death, stillbirth, or both 
in the IPTp-DPmonthly group, omitting neonatal death, and 
modelling neonatal death from low birthweight, all led to 
IPTp-DPmonthly being more cost-effective than IPTp-DP3 for 
all or most cost-effectiveness thresholds. Finally, for 
IPTp-DPmonthly versus IPTp-SPmonthly, although some determin-
istic changes resulted in higher ICERs, IPTp-DPmonthly 
remained cost-effective for at least two cost-effectiveness 
thresholds with all changes (appendix p 19). The largest 
changes to the ICER arose from doubling the risk of both 
stillbirth and neonatal death in the IPTp-DPmonthly group 
(ICER $411 per DALY averted), followed by omitting both 
stillbirth and neonatal death in the model ($136 per DALY 
averted), and by omitting stillbirth and neonatal death plus 
modelling neonatal death from low birthweight ($101 per 
DALY averted).
Discussion
This study brings together all of the currently available 
evidence on the cost-effectiveness of IPTp-DP in 
preventing malaria in pregnancy and its consequences 
for the health of the mother and her baby. Although at 
first glance our findings paint a slightly mixed picture of 
the cost-effectiveness of IPTp-DP, looking at the base 
case analysis together with sensitivity analyses and 
understanding of trial contexts provides a convincing 
interpretation. IPTp-DP3 was highly cost-effective 
compared with IPTp-SP3, with a low estimated ICER of 
$8 per DALY averted and a likelihood of being cost-
effective of at least 97·6%, with respect to all cost-
effectiveness thresholds. When excluding both neonatal 
deaths and stillbirths in the sensitivity analysis, the 
difference in DALYs between IPTp-DP3 and IPTp-SP3 
became negative, as did the ICER (lower efficacy at a 
higher cost), which is primarily caused by a slightly 
higher number of cases of low birthweight in the 
IPTp-DP3 group when compared to IPTp-SP3. By 
contrast, IPTp-DPmonthly was less effective and at higher 
Ignoring neonatal death (neonatal deaths set at 0 for both groups)
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Figure 2: Deterministic sensitivity analysis; tornado diagram of IPTp-DP3 versus IPTp-SP3 using pooled data
The right side of the figure shows a magnified version of the graph for visual clarity. The base case ICER (US$8 per DALY averted) is shown with black arrows in the graph. 12 single parameters were varied 
individually using lower and higher estimates, shown with green bars on the graph, and there were five more structural changes to the model, reflecting that the outcomes driving the cost-effectiveness 
vary among the three trials (Kenya, Uganda-I, and Uganda-II); these changes are shown with orange bars. IPTp-DP3=intermittent preventive treatment in pregnancy with three doses of dihydroartemisinin–
piperaquine. IPTp-SP3=intermittent preventive treatment in pregnancy with three doses of sulfadoxine–pyrimethamine. ICER=incremental cost-effectiveness ratio. DALY=disability-adjusted life-year.
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cost than IPTp-DP3 in the Uganda-I trial, producing a 
negative ICER, mainly due to higher numbers of neonatal 
deaths in the IPTp-DPmonthly group, but the sensitivity 
scenarios excluding or modelling neonatal death 
generated highly cost-effective ICERs ranging from 
$24 to $43 per DALY averted. Lastly, IPTp-DPmonthly versus 
IPTp-SPmonthly produced a highly cost-effective ICER of $25 
per DALY averted. For this comparison, the likelihood of 
cost-effectiveness in the probabilistic sensitivity analysis 
was 58·6% for the lowest cost-effectiveness threshold 
($30·6) and ranged from 89·2% to 93·2% for the second 
to fifth thresholds. The cost-effectiveness remained 
robust in the deterministic sensitivity analysis, with no 
changes producing a negative ICER, and some changes 
producing higher but still cost-effective ICERs.
Over time, national policies have moved from IPTp-SP3 
to IPTp-SPmonthly, enabling the Uganda-I trial to incorporate 
an IPTp-DPmonthly group and the most recent trial, 
Uganda-II, to study IPTp-DPmonthly versus IPTp-SPmonthly. 
We opted to present the cost-effectiveness of the three 
trials and their pooled estimates together to provide 
decision makers with a comprehensive overview of the 
current evidence on the cost-effectiveness of IPTp-DP. 
However, the difference in the sizes of the trials, and the 
implications for the interpretation of the results create 
some challenges and caveats.
In principle, all relevant outcomes should be included 
in a cost-effectiveness analysis (ie, the same criteria 
should be applied consistently when selecting the 
outcomes to include). In this case, the primary outcome 
(DALYs averted by the intervention) is a composite 
outcome, generated by adding together multiple health 
outcomes (eg, low birthweight, maternal anaemia, and 
malaria morbidity and mortality) measured in pregnant 
women and their babies. While in all three trials IPTp-
DP was found to be highly efficacious, this efficacy 
varied for different outcomes across the three trials, with 
IPTp-DP leading to fewer neonatal deaths and stillbirths 
in the Kenya and Uganda-II trials, and fewer low 
birthweight babies in the Uganda-I and Uganda-II trials. 
These differences were particularly relevant when 
comparing IPTp-DPmonthly with IPTp-SP3, because the 
sample size in the Uganda-I trial was much smaller 
(n=100 per group), introducing more uncertainty than 
for the other comparisons. In the Kenya trial (n=500 per 
group), the pooled data, and the Uganda-II trial, 
mortality outcomes (neonatal death and stillbirth) were 
the main drivers of the cost-effectiveness of IPTp-DP. 
However, in the smaller Uganda-I trial there were 
slightly more neonatal deaths in the IPTp-DPmonthly group 
(three deaths vs two in the IPTp-DP3 group and none in 
the IPTp-SP3 group), which becomes magnified when 
cost-effective ness is modelled in a hypothetical cohort of 
1000 women. When these deaths are included in our 
model and DALY calculation, the IPTp-DP groups 
cannot be effective in the Uganda-I trial, and therefore 
not cost-effective, despite a beneficial effect in the 
IPTp-DP groups for low birthweight, clinical malaria, 
and mild maternal anaemia. Modelling neonatal 
mortality from low birthweight instead, provides some 
insight into the potential ICER. An additional death at 
birth contributes so much more to the calculation of 
total DALYs that it offsets all other outcomes. One death 
at birth in the Uganda-I trial contributes 27·6 DALYs 
compared with only 2·9 DALYs per low birthweight 
case and less than 0·3 DALYs for all other outcomes. For 
the aggregated data model, we were faced with the issue 
that when excluding mortality outcomes, there were 
more cases of low birthweight (15·6 more cases per 
1000 pregnant women) in the IPTp-DP3 group than in 
the IPTp-SP3 group. Desai and colleagues suggested 
that the improved survival in the IPTp-DP3 group 
might have resulted in more livebirths with lower 
birthweights.12
The deterministic sensitivity analysis in particular 
highlights the importance of the risk of stillbirth and 
neonatal death for the cost-effectiveness of IPTp-DP. 
Although there is some heterogeneity in the cost-
effectiveness, the analyses based on the pooled data and 
the Uganda-II trial data both produce a highly cost-
effective ICER of $8 or $25 per DALY averted. Their 
cost-effectiveness planes reveal a high proportion of 
simulations being cost-effective for the different cost-
effectiveness thresholds and the ICERs are robust to 
different assumptions being tested in the deterministic 
sensitivity analysis. When we model the cost-
effectiveness of IPTp-DPmonthly compared with IPTp-DP3 
(Uganda-I) by applying a case fatality rate of 6·93% to 
the low birthweight cases, we estimate a highly cost-
effective ICER of $24 per DALY averted. Our findings, 
therefore, suggest that both IPTp-DP regimens are 
likely to be highly cost-effective in settings of comparable 
endemicity and sulfadoxine–pyrimethamine resistance. 
Nevertheless, to be able to confidently judge the cost-
effectiveness of IPTp-DP and decide on the correct 
regimen, larger trials with the monthly regimens in 
settings with similar or higher levels of sulfadoxine–
pyrimethamine resistance are needed.
Our study had several other limitations. Primary cost 
data collection to calculate cost savings of the intervention 
was not undertaken in Uganda, other than ex-post 
collection of nurses’ salary costs. Instead, we have 
adjusted the Kenyan costs to Ugandan price levels using 
a ratio of the average nurses’ salary in the two countries. 
The drug costs of both sulfadoxine–pyrimethamine and 
dihydroartemisinin–piperaquine were calculated from 
international procurement databases and are not expe-
cted to vary between the two countries because of inter-
national procurement for malaria control programmes. 
Although this calculation probably represents the true 
cost of the widely used sulfadoxine–pyrimethamine, it 
might not reflect the actual cost that would be paid if 
IPTp-DP was to be widely adopted as national policy, 
as dihydroartemisinin–piperaquine is currently procured 
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in much smaller quantities. Changing to IPTp-DP in 
several countries would probably reduce the costs of 
dihydro artemisinin–piperaquine, rendering both IPTp-
DP3 and IPTp-DPmonthly more cost-effective than estimated 
in this study. Long-term costs of low birthweight 
babies in low-income and middle-income countries are 
generally unknown; therefore we only included the 
incremental short-term cost of hospitalisation of low 
birthweight compared with normal birthweight babies 
measured in the trial population. This costing greatly 
underestimates the lifetime costs of low birthweight, 
which is particularly relevant for the pooled data, where 
the IPTp-SP group had fewer low birthweight cases. We 
addressed this possible underestimation in the sensitivity 
analysis by exploring the changes to the ICER when 
including two very high arbitrary values of $1000 and 
$5000 as the discounted incremental lifetime cost of 
low birthweight. In both cases, the ICERs remained 
relatively robust and highly cost-effective at $24 and 
$93 per DALY averted.
In the Kenya trial, approximately 10% of the babies were 
not weighed, and Desai and colleagues12 did not report 
whether there were any differences between weighed and 
unweighed babies, nor did the cost-effectiveness analysis 
explore a potential underestimation or overestimation in 
the number of low birthweight babies in a sensitivity 
analysis.
We have described the rationale for using the same 
analytical metrics for all trials. Although a strength of this 
study is that it presents the full available evidence to 
decision makers, the execution and interpretation of the 
analysis require a careful reflection on the differences in 
study design and the results of the individual trials to 
interpret the cost-effectiveness results and sensitivity 
analysis.
In summary, our data suggest that IPTp-DP3 and 
IPTp-DPmonthly are likely to be highly cost-effective in 
areas of high malaria transmission and sulfadoxine–
pyrimethamine resistance, in HIV-negative pregnant 
women with a high uptake of long-lasting insecticidal 
nets. Nevertheless, before a policy change is advocated, 
we recommend further research into the efficacy of IPTp-
DPmonthly in preventing malaria infection during pregnancy 
and its sequelae. Ideally, further research should also 
include malaria prevention in HIV-positive women, who 
continue to rely solely on co-trimoxazole.
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